CoChat
Sign Up
Cited by 158

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Met as a therapeutic target in HCC: Facts and hopes

Giordano, Silvia, Columbano, Amedeo·2014·Journal of Hepatology
DOI 10.1016/j.jhep.2013.09.009
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2013.09.009

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 87

  1. Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107 · DOI
  2. Llovet, 2008, Design and endpoints of clinical trials in hepatocellular carcinoma, J Natl Cancer Inst, 100, 698, 10.1093/jnci/djn134 · DOI
  3. Llovet, 2008, Molecular targeted therapies in hepatocellular carcinoma, Hepatology, 48, 1312, 10.1002/hep.22506 · DOI
  4. Luo, 2009, Principles of cancer therapy: oncogene and non-oncogene addiction, Cell, 136, 823, 10.1016/j.cell.2009.02.024 · DOI · Paper page
  5. Giordano, 1989, Tyrosine kinase receptor indistinguishable from the c-met protein, Nature, 339, 155, 10.1038/339155a0 · DOI
  6. Corso, 2013, Cell autonomous and non-cell autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective, Cancer Discov, 3, 978, 10.1158/2159-8290.CD-13-0040 · DOI
  7. Bottaro, 1991, Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product, Science, 251, 802, 10.1126/science.1846706 · DOI
  8. Naldini, 1991, Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET, Oncogene, 6, 501
  9. Birchmeier, 2003, Met, metastasis, motility and more, Nat Rev Mol Cell Biol, 4, 915, 10.1038/nrm1261 · DOI
  10. Migliore, 2008, Molecular cancer therapy: can our expectation be MET?, Eur J Cancer, 44, 641, 10.1016/j.ejca.2008.01.022 · DOI
  11. van der Voort, 1999, Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met, J Biol Chem, 274, 6499, 10.1074/jbc.274.10.6499 · DOI
  12. Orian-Rousseau, 2002, CD44 is required for two consecutive steps in HGF/c-Met signaling, Genes Dev, 16, 3074, 10.1101/gad.242602 · DOI
  13. Trusolino, 2001, A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth, Cell, 107, 643, 10.1016/S0092-8674(01)00567-0 · DOI
  14. Giordano, 2002, The semaphorin 4D receptor controls invasive growth by coupling with Met, Nat Cell Biol, 4, 720, 10.1038/ncb843 · DOI
  15. Jo, 2000, Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells, J Biol Chem, 275, 8806, 10.1074/jbc.275.12.8806 · DOI · Paper page
  16. Bergstrom, 2000, Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells, Exp Cell Res, 259, 293, 10.1006/excr.2000.4967 · DOI
  17. Fischer, 2004, Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells, J Biol Chem, 279, 28970, 10.1074/jbc.M402508200 · DOI
  18. Lu, 2012, VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex, Cancer Cell, 22, 21, 10.1016/j.ccr.2012.05.037 · DOI
  19. Wang, 2002, A mechanism of cell survival: sequestration of Fas by the HGF receptor Met, Mol Cell, 9, 411, 10.1016/S1097-2765(02)00439-2 · DOI · Paper page
  20. Sakata, 1996, Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers, Cell Growth Differ, 7, 1513
  21. Wang, 2001, Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice, J Cell Biol, 153, 1023, 10.1083/jcb.153.5.1023 · DOI
  22. Takayama, 1997, Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor, Proc Natl Acad Sci U S A, 94, 701, 10.1073/pnas.94.2.701 · DOI
  23. Liang, 1996, Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors, J Clin Invest, 97, 2872, 10.1172/JCI118744 · DOI
  24. Comoglio, 2008, Drug development of MET inhibitors: targeting oncogene addiction and expedience, Nat Rev Drug Discov, 7, 504, 10.1038/nrd2530 · DOI
  25. Schmidt, 1997, Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas, Nat Genet, 16, 68, 10.1038/ng0597-68 · DOI
  26. Michieli, 1999, Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists, Oncogene, 18, 5221, 10.1038/sj.onc.1202899 · DOI
  27. Nakamura, 1984, Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats, Biochem Biophys Res Commun, 122, 1450, 10.1016/0006-291X(84)91253-1 · DOI · Paper page
  28. Nakamura, 1989, Molecular cloning and expression of human hepatocyte growth factor, Nature, 342, 440, 10.1038/342440a0 · DOI
  29. Furlong, 1991, Comparison of biological and immunochemical properties indicates that scatter factor and hepatocyte growth factor are indistinguishable, J Cell Sci, 100, 173, 10.1242/jcs.100.1.173 · DOI
  30. Shima, 1991, Tumor cytotoxic factor/hepatocyte growth factor from human fibroblasts: cloning of its cDNA, purification and characterization of recombinant protein, Biochem Biophys Res Commun, 180, 1151, 10.1016/S0006-291X(05)81187-8 · DOI
  31. Kosai, 1998, Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor, Biochem Biophys Res Commun, 244, 683, 10.1006/bbrc.1998.8293 · DOI
  32. Amicone, 1997, Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes, EMBO J, 16, 495, 10.1093/emboj/16.3.495 · DOI
  33. Wang, 2012, DeLeve LD Liver sinusoidal endothelial cell progenitor cells promote liver regeneration in rats, J Clin Invest, 122, 1567, 10.1172/JCI58789 · DOI
  34. Huh, 2004, Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair, Proc Natl Acad Sci U S A, 101, 4477, 10.1073/pnas.0306068101 · DOI · Paper page
  35. Borowiak, 2004, Met provides essential signals for liver regeneration, Proc Natl Acad Sci U S A, 101, 10608, 10.1073/pnas.0403412101 · DOI · Paper page
  36. Giebeler, 2009, C-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice, Gastroenterology, 137, 308, 10.1053/j.gastro.2009.01.068 · DOI
  37. Aberger, 1996, The Xenopus homologue of hepatocyte growth factor-like protein is specifically expressed in the presumptive neural plate during gastrulation, Mech Dev, 54, 23, 10.1016/0925-4773(95)00458-0 · DOI
  38. Takeo, 2001, Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis, Cancer Genet Cytogenet, 130, 127, 10.1016/S0165-4608(01)00479-4 · DOI
  39. Kondo, 2013, Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma, Int J Clin Oncol, 18, 207, 10.1007/s10147-011-0361-9 · DOI
  40. Wang, 2013, Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma, Hepatology, 58, 706, 10.1002/hep.26402 · DOI
  41. Guichard, 2012, Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma, Nat Genet, 44, 694, 10.1038/ng.2256 · DOI
  42. Jia, 2013, Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion, PLoS One, 8, e63243, 10.1371/journal.pone.0063243 · DOI
  43. Ueki, 1997, Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma, Hepatology, 25, 862, 10.1002/hep.510250413 · DOI
  44. Boix, 1994, C-met mRNA overexpression in human hepatocellular carcinoma, Hepatology, 19, 88, 10.1002/hep.1840190115 · DOI
  45. Suzuki, 1994, Expression of the c-met protooncogene in human hepatocellular carcinoma, Hepatology, 20, 1231, 10.1002/hep.1840200520 · DOI
  46. Noguchi, 1996, Gene expressions of c-met and hepatocyte growth factor in chronic liver disease and hepatocellular carcinoma, J Hepatol, 24, 286, 10.1016/S0168-8278(96)80006-7 · DOI
  47. Kiss, 1997, Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met, TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas, Clin Cancer Res, 3, 1059
  48. Tavian, 2000, U-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma, Int J Cancer, 87, 644, 10.1002/1097-0215(20000901)87:5<644::AID-IJC4>3.0.CO;2-W · DOI
  49. Daveau, 2003, Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma, Mol Carcinog, 36, 130, 10.1002/mc.10103 · DOI
  50. Suzuki, 2005, Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma, J Biol Chem, 280, 6409, 10.1074/jbc.M406714200 · DOI
  51. Gao, 2012, Des-gamma-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence, Biosci Trends, 6, 153, 10.5582/bst.2012.v6.4.153 · DOI
  52. Weitz, 1993, Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review, Hepatology, 18, 990, 10.1002/hep.1840180434 · DOI
  53. Kaposi-Novak, 2006, Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype, J Clin Invest, 116, 1582, 10.1172/JCI27236 · DOI
  54. Shiota, 1992, Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells, Proc Natl Acad Sci U S A, 89, 373, 10.1073/pnas.89.1.373 · DOI
  55. Ogasawara, 1998, Hepatocyte growth factor stimulates DNA synthesis in rat preneoplastic hepatocytes but not in liver carcinoma cells, Gastroenterology, 114, 775, 10.1016/S0016-5085(98)70591-8 · DOI
  56. Nakanishi, 1999, Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase, Clin Exp Metastasis, 17, 507, 10.1023/A:1006685218766 · DOI
  57. Shirako, 2008, Up-regulation of p21CIP1 expression mediated by ERK-dependent and -independent pathways contributes to hepatocyte growth factor-induced inhibition of HepG2 hepatoma cell proliferation, J Cell Biochem, 104, 176, 10.1002/jcb.21614 · DOI
  58. Zhang, 2005, Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo, Mol Cancer Ther, 4, 1577, 10.1158/1535-7163.MCT-05-0106 · DOI
  59. Salvi, 2007, In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells, Int J Oncol, 31, 451
  60. Xie, 2010, Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference, J Surg Res, 162, 231, 10.1016/j.jss.2009.04.030 · DOI
  61. Schmidt, 1995, Scatter factor/hepatocyte growth factor is essential for liver development, Nature, 373, 699, 10.1038/373699a0 · DOI
  62. Uehara, 1995, Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor, Nature, 373, 702, 10.1038/373702a0 · DOI
  63. Takami, 2007, Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis, Cancer Res, 67, 9844, 10.1158/0008-5472.CAN-07-1905 · DOI
  64. Marx-Stoelting, 2009, Hepatocarcinogenesis in mice with a conditional knockout of the hepatocyte growth factor receptor c-Met, Int J Cancer, 124, 1767, 10.1002/ijc.24167 · DOI
  65. Tward, 2005, Genomic progression in mouse models for liver tumors, Cold Spring Harb Symp Quant Biol, 70, 217, 10.1101/sqb.2005.70.058 · DOI
  66. Liu, 1995, Hepatocyte growth factor inhibits cell proliferation in vivo of rat hepatocellular carcinomas induced by diethylnitrosamine, Carcinogenesis, 16, 841, 10.1093/carcin/16.4.841 · DOI
  67. Yaono, 1995, Hepatocyte growth factor enhancement of preneoplastic hepatic foci development in rats treated with diethylnitrosamine and N-ethyl-N-hydroxyethylnitrosamine, Jpn J Cancer Res, 86, 718, 10.1111/j.1349-7006.1995.tb02459.x · DOI
  68. Shiota, 1994, Hepatocyte growth factor in transgenic mice: effects on hepatocyte growth, liver regeneration and gene expression, Hepatology, 19, 962, 10.1002/hep.1840190423 · DOI
  69. Horiguchi, 2002, Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine, Oncogene, 21, 1791, 10.1038/sj.onc.1205248 · DOI
  70. Santoni-Rugiu, 1996, Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model, Proc Natl Acad Sci U S A, 93, 9577, 10.1073/pnas.93.18.9577 · DOI
  71. Shiota, 1995, Characterization of double transgenic mice expressing hepatocye growth factor and transforming growth factor alpha, Res Commun Mol Pathol Pharmacol, 90, 17
  72. Zhang, 2003, Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation, Proc Natl Acad Sci U S A, 100, 12718, 10.1073/pnas.2135113100 · DOI
  73. Eckerich, 2007, Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration, Int J Cancer, 121, 276, 10.1002/ijc.22679 · DOI
  74. Pennacchietti, 2003, Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene, Cancer Cell, 3, 347, 10.1016/S1535-6108(03)00085-0 · DOI · Paper page
  75. Rose, 2010, Mechanisms of evasion to antiangiogenic therapy in glioblastoma, Clin Neurosurg, 57, 123
  76. Huynh, 2012, Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma, Angiogenesis, 15, 59, 10.1007/s10456-011-9243-z · DOI
  77. Martell, 2012, Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study (abstract), J Clin Oncol, 30, abstr 4117, 10.1200/jco.2012.30.15_suppl.4117 · DOI
  78. Munshi, 2010, ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity, Mol Cancer Ther, 9, 1544, 10.1158/1535-7163.MCT-09-1173 · DOI
  79. Santoro, 2013, Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study, Lancet Oncol, 14, 55, 10.1016/S1470-2045(12)70490-4 · DOI
  80. Katayama, 2013, Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition, Cancer Res, 73, 3087, 10.1158/0008-5472.CAN-12-3256 · DOI
  81. Basilico, 2013, Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET, Clin Cancer Res, 19, 2381, 10.1158/1078-0432.CCR-12-3459 · DOI
  82. O’Shaughnessy, 2011, Iniparib plus chemotherapy in metastatic triple-negative breast cancer, N Engl J Med, 364, 205, 10.1056/NEJMoa1011418 · DOI · Paper page
  83. Liu, 2012, Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor, Clin Cancer Res, 18, 510, 10.1158/1078-0432.CCR-11-1973 · DOI
  84. Patel, 2012, Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro, Clin Cancer Res, 18, 1655, 10.1158/1078-0432.CCR-11-2890 · DOI
  85. Yau, 2012, A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC), J Clin Oncol, 30, 4108, 10.1200/jco.2012.30.15_suppl.4108 · DOI
  86. Verslype, 2012, Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT), J Clin Oncol, 30, 4007, 10.1200/jco.2012.30.15_suppl.4007 · DOI
  87. Selden, 1994, Expression of hepatocyte growth factor mRNA, and c-met mRNA (hepatocyte growth factor receptor) in human liver tumours, J Hepatol, 21, 227, 10.1016/S0168-8278(05)80400-3 · DOI

Cited by

Sorted by citations

Metadata

Authors
Giordano, S., & Columbano, A.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2014-02
Volume
60
Issue
2
Pages
442-452
ISSN
0168-8278
DOI
10.1016/j.jhep.2013.09.009
Cited by
158
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review